Combined modality therapy with TRAIL or agonistic death receptor antibodies.
about
Computational modelling of LY303511 and TRAIL-induced apoptosis suggests dynamic regulation of cFLIPSuperior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivityWEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.Molecular targeted approaches for treatment of pancreatic cancer.Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cellsLow-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosishnRNPK inhibits GSK3β Ser9 phosphorylation, thereby stabilizing c-FLIP and contributes to TRAIL resistance in H1299 lung adenocarcinoma cells.Effect of anti-DR5 and chemotherapy on basal-like breast cancer.Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.Molecular Signaling in Benign Odontogenic Neoplasia PathogenesisTRAIL on trial: preclinical advances in cancer therapyEngineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironmentSensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.Using natural products to promote caspase-8-dependent cancer cell death.Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules.Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis.TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA.The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.
P2860
Q28393929-8B2F7B0E-09A0-41AD-BED0-7B499A65F220Q28729760-3D77C101-F55F-4EBE-AEDE-5E94CE81EB99Q35683131-12B895C2-0236-4591-A90F-67E04137CC16Q36174910-64DCD9FA-952C-48C5-A14C-1315CC17B91BQ36218165-BFFAFBFB-AB03-40E2-99C2-39E5B28BAB2AQ36339240-FEE6C4BB-A127-45AD-8C7C-A527ECA32E90Q36608713-3F96C181-767E-42F2-9ED9-B02781926773Q36681641-1B45FC50-6F4E-4207-89A4-14CB46BD17EEQ36731275-9B19CC43-E77C-493F-BAFC-5E1A6906817AQ36962657-FD3BCF80-1277-421A-9951-5B1CEF5E65B1Q37183900-57811C0E-FD40-4C04-B992-66BC86070F48Q37433463-45EF71AD-E65C-4359-9A77-E72A7EAA4AC1Q37482834-F9BADE15-7B32-41B2-A378-68318B5BC0A5Q37520325-0B8270E2-E495-4868-811F-C96FB0EC0790Q37992502-E88AEC27-5410-4CE3-8CC8-18157ACF04FDQ38861356-B64D5826-4401-4EC2-9958-C49ABACDEF09Q39126075-AFEB1BA6-D27E-4184-8773-36290438BAE4Q39272664-31E7742B-FA69-4BB2-95C3-DBE24A8A55E7Q39392672-5BFCA373-6CF0-46C9-907C-9719C2DC8BB6Q39406143-E0279B6F-DE98-4AD6-9918-DF059A855F97Q41987802-75EC5F22-3024-4E25-850A-E45BE49C53DFQ43468001-19991236-57EA-47C1-9749-DC86E9BDFC59
P2860
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
@en
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
@nl
type
label
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
@en
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
@nl
prefLabel
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
@en
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
@nl
P2093
P2860
P356
P1476
Combined modality therapy with TRAIL or agonistic death receptor antibodies
@en
P2093
Choo Hyung Lee
Hope M Amm
Patsy G Oliver
P2860
P304
P356
10.4161/CBT.11.5.14671
P577
2011-03-01T00:00:00Z